Completed OBSERVATIONAL NCT03164018

Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis (FAMILY)

Sponsor: Genesis Pharma CNS & Specialty

Interventions Fampridine

Updated 8 times since 2017 Last updated: Feb 13, 2019 Started: Mar 7, 2017 Primary completion: Dec 15, 2018 Completion: Dec 15, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03164018, this observational or N/A phase trial focuses on Multiple Sclerosis and remains completed. Sponsored by Genesis Pharma CNS & Specialty, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Mar 2019 — Jan 2021 [monthly]

Completed

Status: Active Not Recruiting → Completed
Aug 2018 — Mar 2019 [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Recruiting
Apr 2018 — Jun 2018 [monthly]

Recruiting

Phase: NA → None
Jun 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genesis Pharma CNS & Specialty

Data source: Genesis Pharma CNS & Specialty

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Athens, Greece